HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rury R Holman Selected Research

Exenatide (Byetta)

1/2022A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.
1/2022Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.
1/2021Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
1/2021Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
1/2020Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
1/2020Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
1/2020Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
1/2020Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
12/2019Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
11/2019Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rury R Holman Research Topics

Disease

96Type 2 Diabetes Mellitus (MODY)
01/2022 - 02/2002
40Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 05/2002
23Myocardial Infarction
01/2022 - 10/2008
21Stroke (Strokes)
12/2020 - 04/2010
20Heart Failure
01/2022 - 12/2006
20Glucose Intolerance
12/2020 - 10/2006
11Insulin Resistance
01/2021 - 10/2002
9Hypoglycemia (Reactive Hypoglycemia)
12/2019 - 02/2002
8Atrial Fibrillation
10/2021 - 01/2012
7Hypertension (High Blood Pressure)
01/2022 - 11/2004
7Unstable Angina
12/2019 - 04/2010
7Diabetes Mellitus
12/2019 - 07/2006
7Weight Gain
01/2018 - 02/2002
6Hyperglycemia
05/2012 - 05/2002
5Body Weight (Weight, Body)
01/2022 - 02/2002
5Coronary Disease (Coronary Heart Disease)
12/2020 - 09/2013
5Renal Insufficiency (Renal Failure)
01/2020 - 06/2013
4Neoplasms (Cancer)
01/2022 - 11/2017
4Diabetic Retinopathy (Retinopathy, Diabetic)
01/2022 - 11/2004
4Vascular Diseases (Vascular Disease)
12/2021 - 01/2016
4Obesity
01/2020 - 08/2006
4Blindness (Hysterical Blindness)
01/2020 - 06/2013
4Pancreatitis
01/2018 - 02/2017
3Albuminuria
10/2021 - 06/2006
3Peripheral Arterial Disease
10/2021 - 03/2009
3Type 1 Diabetes Mellitus (Autoimmune Diabetes)
07/2020 - 06/2006
3Pancreatic Neoplasms (Pancreatic Cancer)
01/2018 - 02/2017
3Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2017 - 08/2006
3Overweight
04/2015 - 11/2006
2Weight Loss (Weight Reduction)
01/2022 - 04/2015
2Infections
10/2021 - 01/2020
2Chronic Renal Insufficiency
01/2021 - 11/2017
2Acute Coronary Syndrome
01/2021 - 01/2020
2Inflammation (Inflammations)
01/2020 - 08/2006
2Edema (Dropsy)
01/2018 - 12/2006
2Eye Diseases (Eye Disease)
11/2017 - 07/2006
2Bone Fractures (Bone Fracture)
11/2017 - 01/2010
2Chronic Kidney Failure (Chronic Renal Failure)
01/2017 - 01/2017
2Diabetes Complications
06/2013 - 11/2006
1Rheumatoid Arthritis
01/2022
1Gangrene
10/2021
1Peripheral Vascular Diseases (Peripheral Vascular Disease)
10/2021
1Foot Ulcer
10/2021
1Coronary Artery Disease (Coronary Atherosclerosis)
10/2021
1Orthostatic Hypotension (Postural Hypotension)
01/2021
1Lactic Acidosis
01/2021

Drug/Important Bio-Agent (IBA)

30Glucose (Dextrose)FDA LinkGeneric
01/2022 - 08/2002
24Sitagliptin Phosphate (Januvia)FDA Link
01/2022 - 12/2013
18Exenatide (Byetta)FDA Link
01/2022 - 04/2016
18Metformin (Glucophage)FDA LinkGeneric
01/2021 - 10/2002
15Valsartan (Vals)FDA Link
10/2020 - 10/2008
14Nateglinide (Starlix)FDA LinkGeneric
10/2020 - 10/2008
12Insulin (Novolin)FDA Link
10/2021 - 02/2002
9LipidsIBA
01/2022 - 07/2006
9LDL CholesterolIBA
10/2021 - 06/2006
9Pharmaceutical PreparationsIBA
12/2020 - 10/2002
8HDL CholesterolIBA
01/2022 - 05/2002
8Rosiglitazone (Avandia)FDA Link
05/2011 - 10/2002
7CreatinineIBA
01/2022 - 06/2006
7Hypoglycemic Agents (Hypoglycemics)IBA
01/2020 - 10/2007
6omega-Chloroacetophenone (Mace)IBA
12/2021 - 01/2019
6Dipeptidyl-Peptidase IV InhibitorsIBA
12/2020 - 07/2015
6Glyburide (Glibenclamide)FDA LinkGeneric
05/2011 - 10/2002
5Hemoglobins (Hemoglobin)IBA
01/2022 - 12/2013
5AcarboseFDA LinkGeneric
10/2021 - 07/2014
5Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2021 - 01/2018
5ThiazolidinedionesIBA
10/2020 - 12/2006
4Biomarkers (Surrogate Marker)IBA
01/2020 - 01/2010
4Glucagon-Like Peptide-1 ReceptorIBA
12/2019 - 04/2016
4Triglycerides (Triacylglycerol)IBA
01/2018 - 01/2004
4C-Reactive ProteinIBA
02/2014 - 10/2002
4AlbuminsIBA
01/2012 - 10/2002
3SodiumIBA
01/2021 - 10/2019
3Sodium-Glucose Transporter 2 InhibitorsIBA
12/2020 - 10/2019
3Blood Glucose (Blood Sugar)IBA
07/2020 - 02/2014
3Retinaldehyde (Retinal)IBA
01/2020 - 11/2002
3GlucosidasesIBA
01/2020 - 07/2014
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2019 - 03/2009
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
09/2017 - 02/2014
3Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
09/2017 - 11/2004
3CholesterolIBA
01/2012 - 08/2006
3Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
10/2009 - 12/2006
2empagliflozinIBA
01/2021 - 01/2020
2AutoantibodiesIBA
01/2020 - 11/2006
2Glucagon-Like Peptide 1 (GLP 1)IBA
12/2019 - 01/2017
2Glycoside Hydrolase InhibitorsIBA
10/2019 - 01/2018
2Angiotensin Receptor AntagonistsIBA
09/2017 - 10/2012
2AntigensIBA
08/2006 - 10/2002
2Fibrinogen (Factor I)FDA Link
08/2006 - 10/2002
1AnthracyclinesIBA
01/2022
1Fenofibrate (CiL)FDA LinkGeneric
01/2022

Therapy/Procedure

34Therapeutics
01/2022 - 02/2002
11Glycemic Control
01/2020 - 02/2002
5Surgical Amputation (Amputations)
10/2021 - 06/2013
4Light Coagulation
01/2020 - 11/2002
3Precision Medicine
01/2022 - 01/2018
2Drug Therapy (Chemotherapy)
01/2022 - 12/2006
2Secondary Prevention
11/2017 - 09/2017
1Lasers (Laser)
01/2022
1Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2022